InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,164.32
(
0.71%
)
US TECH 100
17,532.00
(
0.65%
)
Dow Jones
38,812.46
(
0.35%
)
Brent Oil
82.87
(
-0.31%
)
Bitcoin
63,220.85
(
-1.20%
)
Post# of 251726
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119575
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193522

Wednesday, 09/02/2015 11:00:30 AM

Wednesday, September 02, 2015 11:00:30 AM

Post# of 251726
GILD’s F/TAF non-inferior to Truvada on efficacy at 48w and superior on two safety metrics (BMD and eGFR):

http://finance.yahoo.com/news/gilead-investigational-fixed-dose-combination-123000652.html

These results were expected based on other data comparing TAF-based regimens to their corresponding Viread-based regimens. The PDUFA date for F/TAF is 4/7/16.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up